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Abstract
Background: Protein secretion by mammary cells results in autocrine and paracrine signaling that defines cell
growth, migration and the extracellular environment. Even so, we have a limited understanding of the cellular
processes that regulate protein secretion.
Methods: In this study, we utilize human epithelial mammary cell (HMEC) lines that were engineered to express
different levels of HER1, HER2 and HER3. Using an ELISA microarray platform, we evaluate the effects of epidermal
growth factor family receptor (HER) expression on protein secretion in the HMEC lines upon initiation of HER1
receptor activation. The secreted proteins include three HER1 ligands, interleukins 1a and 18, RANTES, vascular-
endothelial and platelet-derived growth factors, matrix metalloproteases 1, 2 and 9, and the extracellular portion of
the HER1 and HER2 proteins. In addition, we investigate whether MAPK/Erk and PI3K/Akt signaling regulate protein
secretion in these cell lines and if so, whether the involvement of HER2 or HER3 receptor alters their response to
MAPK/Erk and PI3K/Akt signal pathway inhibition in terms of protein secretion.
Results: Differential expression of HER2 and HER3 receptors alters the secretion of a variety of growth factors,
cytokines, and proteases. Some alterations in protein secretion are still observed when MAPK/Erk or PI3K/Akt
signaling is inhibited.
Conclusion: This study suggests that HER overexpression orchestrates broad changes in the tumor
microenvironment by altering the secretion of a diverse variety of biologically active proteins.
Background
The family of human epidermal growth factor (EGF)
tyrosine kinase receptors (HER) includes HER1 (also
known as the EGF receptor), HER2, HER3 and HER4.
These receptors play important roles in diverse cellular
processes, including but not limited to, cell growth, pro-
liferation and migration [1]. Once activated, HER recep-
tors initiate the recruitment of intermediate signaling
proteins, which subsequently activate downstream signal
cascades that trigger the cellular responses [2]. HER2
receptors lack a ligand-binding domain and HER3
receptors lack intrinsic tyrosine kinase activity [3]. Even
so, HER2 and HER3 form dimers with other ligand-
bound HER receptors, and thereby participate in signal
transduction. Upon ligand binding, HER1 and HER4 are
quickly phosphorylated and activated. Receptor activa-
tion can result in the release of their cognate ligands,
which then act as a positive feedback loop through auto-
crine/paracrine signaling.
Aberrant HER receptor signaling, either due to overex-
pression or mutation of one or more HER receptors or
due to abnormal production of their ligands, contributes
to the development and progression of a broad spectra of
human cancers, including breast, colon, lung, ovarian,
and head and neck cancers [4-7]. Since portions of these
proteins are all released to the extracellular environment,
HER receptors and their ligands are not only potential
therapeutic targets for the treatment of these cancers, but
also potential cancer biomarkers [8-11].
A number of HER ligands have been identified as can-
cer biomarkers, including EGF, amphiregulin (AREG),
heparin-binding EGF-like growth factor (HB-EGF), and
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transforming growth factor-a (TGF-a) [12-14]. These
ligands are tightly associated with HER receptor expres-
sion in a variety of cancer types. For example, studies
have demonstrated a number of HER ligands are
expressed and correlated with expression of HER recep-
tors in breast cancer patients, and high expression of
certain HER ligands are related to the biological aggres-
siveness of the tumors [15]. All of these ligands are initi-
ally synthesized as membrane-anchored proteins [3].
Soluble ligands are released through a process called
“shedding”, which involves proteolytic cleavage on the
extracellular side of the transmembrane domain. Shed-
ding is the last step in the secretion of the biologically
active ectodomain of the ligands. Similar to HER
ligands, HER receptors undergo shedding during both
physiological and pathological conditions. In general,
this process is thought to represent one of several feed-
back mechanisms that prevent prolonged receptor acti-
vation. Metalloproteases, including the disintegrin and
metalloproteases (ADAMs), are recognized as the major
mediators of receptor and ligand ectodomain shedding
[3,16,17].
Serum concentrations of secreted HER ligands and
HER receptors have been investigated rigorously as
potential prognostic factors and therapeutic indicators
for many cancer types. However, numerous studies sug-
gest that no single protein biomarker assay may have
sufficient sensitivity and specificity to be used clinically,
especially for early detection. In particular, the tumor
microenvironment appears to be a highly regulated sys-
tem. Its secretome consists of substantial numbers of
proteins that are processed through regulated secretory
pathways. There is considerable evidence that secretion
of these proteins is altered due to a variety of physiolo-
gical or pathological conditions. Therefore, in addition
to HER receptors and ligands, many other groups of cir-
culating proteins have been examined as potential prog-
nostic factors in diagnosis of human cancers.
One such group of proteins is the cytokines [18,19]. In
the pathogenesis of carcinogenesis, pro-inflammatory
cytokines such as interleukin-1a (IL-1a), tumor necrosis
factor (TNFa), and regulated upon activation, normal T
cell expressed and secreted (RANTES), can regulate
host responses to infection, inflammation and various
immune responses. Pro-inflammatory cytokines can also
induce expression of adhesion molecules and metallo-
proteases, both of which are involved in the process of
tumor invasion [20]. Besides cytokines, fibrogenic and
angiogenic factors, including basic fibroblast growth fac-
tor (bFGF) [21], platelet-derived growth factor (PDGF)
[22], vascular endothelial growth factor (VEGF) [23],
hepatocyte growth factor (HGF) [24], insulin-like growth
factor (IGF) [25], are capable of stimulating mitogen sig-
naling pathways and are involved in a wide variety of
cellular processes. Although these proteins are not
known to directly interact with the HER receptors, it
has been demonstrated that most of them can manipu-
late HER-regulated signal pathways, commonly by trans-
activation of these receptors [26-28]. Furthermore,
increased expression of these proteins in breast cancer
is associated with overexpression of HER family mem-
bers [29,30]. Hence, an evaluation of the relationship
between HER expression and cytokines may add valu-
able information for cancer prognostics.
In regard to potential biomarkers like growth factors
and cytokines, there has been a great deal of research
on how these proteins alter epithelial cell function and
downstream cell-signaling pathways. In contrast, there is
very little known about how changes in epithelial cell
processes regulate the secretion of these proteins. A bet-
ter understanding of these cellular mechanisms is
needed if we are to gain useful mechanistic insight into
tumor biology based on circulating biomarker data.
Recent evidence suggests that circulating levels of breast
cancer biomarkers vary with stage [31] and with HER2
receptor status [19]. In this study, we use human mam-
mary epithelial cell lines (HMEC) expressing different
levels of HER receptors to examine effects on the secre-
tion patterns of these potential biomarkers. HER1-3 are
the most commonly studied HER receptors. Therefore,
we focused our study on a parental HME cell line with
endogenous HER1 expression, as well as derived cell
lines that were transfected to overexpress either HER2
or HER3, while still maintaining the basal HER1 expres-
sion. Since these HMEC lines were originally derived
from normal breast cells, they are not carcinoma cell
lines, and are similar to normal mammary epithelial
cells in that they require HER1 activation for proper
proliferation and migration responses [32]. In this study,
we treat cells with a single concentration of EGF to acti-
vate HER1, and then examine the effects on protein
secretion in all three HMEC lines. Overall, this study
provides novel insight into the underlying molecular
processes that regulate biomarker secretion and illus-
trates how HER2 and HER3 co-expression can affect the
secretion of a variety of bioactive proteins that are
important in breast cancer development.
Methods
Materials
EGF (human recombinant) was purchased from Pepro-
tech (Rocky Hill, NJ). Protease inhibitor cocktail III, as
well as all signaling pathway inhibitors, including PI3-
kinase inhibitors LY 294002 and wortmannin, MEK
inhibitors PD 98059 and U0126, were purchased from
Calbiochem (La Jolla, CA). All capture and detection
antibodies, including the commercial source and catalog
numbers, that were used here for the sandwich ELISA
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protein microarrays have been previously described [33].
All other reagents were from Sigma Chemical Company
(St. Louis, MO), unless otherwise indicated.
Generation of HER Cell Lines
Human mammary epithelial cell line (HMEC) 184A1L5
was graciously provided by Martha Stampfer (Lawrence
Berkeley Laboratory, Berkeley, CA) and maintained at
37 °C in 5% CO2/air in DFCI-1 medium supplemented
with 12.5 ng/ml EGF as described [34,35].
Both HER2 and HER3 expressing cell lines were
derived using a retrovirus-based strategy, as described
previously [36,37]. Briefly, transfected cells expressing
HER2 or HER3 were screened in DFCI-1 medium with
the addition of 250 μg/ml G418 (InVitrogen, Carlsbad,
CA) or 2 μg/ml puromycin (Sigma, St. Louis, MO),
respectively. The abundances of HER receptors on these
transfected cells were characterized using flow cytome-
try, with Alexa-488 conjugated mAb 7C2 against HER2
and phycoerythrin conjugated anti-HER3 antibody (R&D
Systems Inc., Minneapolis, MN). Individual clones of
retrovirus transfected HMEC were isolated using cloning
rings (Fisher Scientific Inc., Pittsburgh, PA). Expression
levels of HER receptors were determined by flow cyto-
metry and western blotting.
Three cell lines were examined in this study. They
include the parental cell line 184A1L5 expressing endo-
genous HER1, which is abbreviated as parental “HER1”
cell line in this study. The transfected cell line that over-
expresses HER2, as well as the basal HER1 receptor, is
abbreviated as “HER2” cell line here; the transfected cell
line that overexpresses HER3, as well as the basal HER1
receptor expression, is abbreviated as the “HER3” cell
line. Levels of the HER receptors in these cell lines were
quantified as described before [36,37]. Results from this
analysis showed that there are approximately 2x105
HER1, 3x104 HER2 and 2x103 HER3 receptors on each
parental HER1 cell, 1.5x105 HER1, 6x105 HER2 and
2x103 HER3 on each HER2 cell, and 2x105 HER1, 3 104
HER2 and 2.8 104 HER3 on each HER3 cell. It has been
reported that the well characterized breast cancer cell
line SK-BR3 express about 2x105 HER1, 6x105 HER2
and 1x104 HER3 receptors [38,39]. Based on these
reports and another evaluation of HER receptor concen-
trations in breast cancer cells [40], our HER2 or HER3
cell lines express HER2 or HER3, respectively, at levels
that are comparable to those found in breast cancer
cells that overexpress these receptors.
Cell Culture and Treatment
Only cells that were less than fifteen passages from the
original frozen stock were used in this study. Each cell
line was seeded at 3.0x105 cells per well of 6-well plates
(BD Falcon, Franklin Lakes, NJ) in DFCI-1 culture
medium, and were allowed to grow to confluence prior
to treatment. Before EGF treatment, cultured cells were
fasted for 14-18 h in serum-free, DFCI-1 medium that
lacked all supplements except 0.1% bovine serum albu-
min. Cells were then washed twice with buffered saline,
pH 7.2-7.4 (PBS), followed by the addition of 1 ml fresh
serum-free medium with 12 ng/ml EGF added. Acti-
vated cells were incubated at 37 °C for up to 24 h and
samples were collected at fixed time points after EGF
addition. Immediately prior to harvesting, cells were
chilled by placing the culture dishes on ice.
Sample Collection and Processing
Conditioned medium (CM) from the cultured cells was
transferred to microcentrifuge tubes, and centrifuged at
2000 g for 5 min at 4 °C in order to remove any particu-
lates or cell debris. An aliquot of each supernatant was
then transferred to another tube that contained a 1/10th
volume of 1% casein and green fluorescent protein in
PBS (Bio-Rad, Hercules, CA), such that the final con-
centration of the green fluorescent protein was 100 pg/
ml. Green fluorescent protein was used as the antigen in
an internal calibrant assay based on a sandwich ELISA.
The fluorescent signal from the capture antibody in this
assay was used for data normalization using a custom
bioinformatics program, ProMAT Calibrator, as
described below. The cells on these culture plates were
then washed twice with cold PBS, and harvested by add-
ing 200µl of lysis buffer (50 mM pH 7.4 HEPES, 150
mM NaCl, 0.5% NP40, 1 mM PMSF, 1 mM Na3VO4
and 1% protease inhibitor cocktail III). Cell lysates were
collected and centrifuged at 18,500 g for 10 min. The
protein concentration of cell lysates was measured using
the Bicinchoninic Acid protein quantitation kit (Sigma,
St. Louis, MO) and averaged (± standard deviation)
1.6 ± 0.3 mg/ml. Since 200µl of lysis buffer was added,
we estimate that about 0.32 mg of protein was collected
from each plate.
In certain experiments, cultured cells were pre-incu-
bated with a single inhibitor for 1 h prior to EGF addition.
These inhibitors, and their concentrations, were 20 µM LY
294002, 0.2 µM Wortmannin, 25 µM PD98059, 10 µM
U0126. Stock solutions of each reagent were individually
prepared in DMSO and the final concentration of DMSO
in the culture medium was 0.1% in all treatments, includ-
ing controls. At least two independent experiments were
performed, with five biological replicates (i.e., five cell cul-
ture dishes that were individually processed) in each
experiment, for all results described here. Samples were
stored at -80°C until analysis.
ELISA Microarray Analysis
Concentrations of individual proteins in CM and cell
lysates were quantitatively measured using sandwich
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enzyme-linked immunosorbent assay (ELISA), as pre-
viously described in detail [33]. Briefly, ELISA microarray
chips were custom manufactured using aminosilanated,
25x75 mm glass slides (Erie Scientific, Portsmouth, NH)
stamped with a hydrophobic barrier that was used to cre-
ate 16 wells on each slide. The ELISA reagents used in
these analyses have been previously evaluated and shown
to have no cross-reactivity and to be able to quantita-
tively detect purified antigens that were spiked into
human serum [41]. The capture antibodies were sus-
pended in PBS at concentrations ranging from 0.5 to
1.0 mg/ml. These antibodies were printed using a GeSiM
noncontact NanoPlotter NP2 printer (Quantum Analy-
tics, Foster City, CA). Sixteen identical chips were printed
on each slide, such that each chip was isolated by a
hydrophobic barrier. Each capture antibody and control
reagent was printed in quadruplicate (once in each quad-
rant) on each chip. Successful printing was confirmed
using the RedReflect capability on the ScanArray
ExpressHT (PerkinElmer, Santa Clara, CA) laser scanner.
The printed slides were blocked with 1% casein in PBS at
4 °C and, after washing, stored desiccated and under
vacuum at -20°C until use.
In order to generate standard curves for each of the
ELISA analyses, a single mixture containing all the anti-
gens was prepared in 0.1% casein in PBS and containing
100 pg/ml green fluorescent protein. This stock solution
of the standard mixture was aliquoted and stored at -80°
C, and an aliquot was thawed on a daily basis for each
ELISA microarray analyses. For this analysis, the stan-
dard stock solution was serially diluted 3-fold to create
at least 7 dilutions of the standard mixture. Each dilu-
tion, and an antigen-free blank, was analyzed on three
seperate chips.
Several incubation steps are included in processing the
ELISA microarray chips [41]. Washes were performed
between each incubation step by submerging the slides
in PBS containing 0.05% Tween-20 (PBS-T). Either 20
μl of the standard mixture or an individual, diluted sam-
ple was then pipetted onto each of three replicate chips.
Samples were then incubated overnight in a closed
chamber with saturated humidity and gentle mixing.
Slides were then incubated with a cocktail of all detec-
tion antibodies in 0.1% casein/PBS buffer for 2 h. The
level of biotinylation was then increased using the bioti-
nyltyramide amplification system (Perkin-Elmer). Finally,
slides were submerged in 1 μg/ml of Cy3- or Alexa 647-
conjugated streptavidin in PBS-T, and incubated for 1 h
in dark. Slides were then quickly rinsed with deionized
water and dried. These slides were imaged with a Sca-
nArray Express HT laser scanner. ScanArray Express
software was used to quantify the spot fluorescence
intensity from the scanned images. Spot fluorescent data
were then processed and analyzed using Protein
Microarray Analysis Tool (ProMAT) and ProMAT Cali-
brator [42-44], both of which are open-source, freeware
programs (available at http://www.pnl.gov/statistics/Pro-
MAT/) that we developed specifically for processing
ELISA microarray data. Standard curves were fit to a
four-parameter logistic model and used to estimate the
individual protein concentrations in each sample.
RT-PCR Analysis
Quantitative assessment of mRNA expression was per-
formed by real-time RT-PCR. Total RNA was extracted
using RNeasy kit (Qiagen, Valencia, CA). The HMECs
used in the quantitative RT-PCR analyses were cultured
and harvested in parallel with the cells used in the com-
parable protein experiments in the CM and cell lysates,
although the RNA studies were conducted using cells
raised in seperate dishes. Complementary DNA were
synthesized from total RNA via reverse transcription
using ImProm II reagents (Promega, Madison, WI) and
oligo-dT priming. The following primers were employed
in the quantitative real-time RT-PCR:
cyclophilin A, forward GAGCTGTTGCAGACA
AAGTTC and reverse CCCTGGCACATGAATCCTGG;
AREG, forward CGGAGAATGCAAATATATAGAG-
CAC and reverse CGTTCACCGAAATATTCTTGC;





GTCC and reverse ATGGTGATCTTCTTGCGGC
TCTTGC.
PCR reactions were carried out in a Roche Lightcycler
II using 20 ng cDNA and FastStart DNA MasterPLUS
SYBR Green I reagent according to the manufacturer’s
instructions (Roche Applied Science, Indianapolis, IN).
The PCR cycle parameters were set as denaturation at
95 °C for 10 s, annealing at 55 °C for 5 s and elongation
at 72 °C for 10 s for 45 cycles. Melting curve analyses
were performed from 60 °C to 95 °C in 0.5 °C incre-
ments. RNA from individual cell culture plates was pre-
pared for each treatment group in five replicates.
Quantitative RT-PCR data for AREG, TGF-a, IL-1a,
and RANTES were normalized based on cyclophilin A
transcriptional level [45].
Quantification of Erk/Akt activation
Phosphorylated Erk1 and Akt levels of cell lysates were
quantified by conventional ELISA techniques in a
96-well microplate. R&D System’s DuoSet IC ELISA kits
were used in these measurements, as described before
[37]. The manufacture’s protocols, including the lysis
buffer, were followed in all the ELISA measurements.
Before each ELISA assay, protein concentrations of the
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cell lysates were measured using the Bicinchoninic Acid
protein quantitation kit (Sigma, St. Louis, MO).
Data Analysis
Concentrations of secreted proteins are presented in pg
per ml of conditioned medium (CM). The total volume
of medium/dish was a constant within and across stu-
dies. Concentrations of individual proteins in cell lysates
are presented in ng per mg lysate protein. We used total
(i.e., accumulated) secreted protein in the temporal stu-
dies for comparisons across the cells lines. An alterna-
tive approach would have been to use non-stimulated
cells as the control, and present the difference between
stimulated and non-stimulated cells. This approach was
not used because the cells were first fasted overnight in
serum-free medium. To continue to deprive the cells of
growth factors would have led to cell death during the
remaining 24 hr study, and therefore was not a reason-
able option. Rather, the approach used allowed us to
compare cell lines in parallel and directly demonstrate
the involvement of HER2 or HER3 in protein secretion
following HER1 activation.
Statistical differences between cell lines following EGF
stimulation and/or signaling pathway inhibition were
initially determined by analysis of variance, and then
delineated using Fisher’s protected least significant dif-
ference test using StatView 5.0.1 software (SAS Insti-
tute). A significance level of 0.05 was used in all cases.
Results
Presence of HER2/HER3 Regulates HER Receptor Ligand
Shedding in HMEC
In this study, three HMEC lines, each expressing differ-
ent levels of HER receptors, were stimulated with
12 ng/ml EGF. These cell lines were used to determine
if expression of different HER receptors would affect
secretion of selected proteins, especially the HER1
ligands that are shed and thereby further activate HER1
signaling by an autocrine process. A proteomics analysis
found that the parental HER1 line used here expresses
three HER1 ligands: AREG, HB-EGF and TGF-a [46].
Here, we examined the concentration change of these
three shed ligands in the CM, together with EGF, which
is an exogenous HER1 ligand that was added to the cul-
ture medium.
EGF is the only HER1 ligand that was added to the
culture medium, and it has previously been shown not
to be synthesized by HMEC cells [46]. We therefore sur-
mise that decreasing EGF concentrations in the CM
must reflect EGF consumption. EGF is typically con-
sumed by receptor binding, endocytosis and lysosomal
degradation. The initial EGF concentration was 12 ng/
ml, which saturates the ELISA analysis. The EGF con-
centration remained saturating in the CM from the
HER1 cells for the first 8 h and dropped to ~1.5 ng/ml
at 24 h time point, indicating that EGF was consumed
but still remained at the ng/ml level throughout the
time course for the parental HER1 cell line. In contrast,
the EGF concentration in the CM of HER2 and HER3
cell lines dropped to the pg/ml level at the 24 h time
point, indicating a faster EGF consumption rate in these
two cell lines (Figure 1A).
Temporal concentration patterns of the other three
HER1 ligands, AREG, HB-EGF and TGF-a, are pre-
sented in Figure 1B-1D. Rapid and prominent ligand
accumulation in the CM was detected in all three cell
lines during the first 8 h after initiation of EGF stimula-
tion, with a relatively higher ligand accumulation rate in
HER3 cells. Between 8 and 24 h, in most cases, there
was no significant or even reduced ligand accumulation,
especially in HER2 and HER3 cell lines. Presumably, the
attenuation of ligand accumulation in the CM collected
from these two cell lines resulted from ligand consump-
tion by HMEC. This seems likely, since ligand consump-
tion would be expected to be accelerated upon the
depletion of EGF, which is a competitor for the HER1
receptor and receptor-mediated ligand degradation.
HER2/HER3 Increase AREG and TGF-a Expression and
Shedding
The amount of HER1 ligand shedding can potentially be
modulated by either the synthesis of their membrane-
anchored protein precursors or the activity of the pro-
teolytic enzymes responsible for their shedding. As
differences in ligand shedding was observed between the
HMEC lines that express different HER receptors, we
examined levels of these ligands in cell lysates. The
sandwich ELISA used here should detect the cleaved
(i.e., soluble, biologically active) ligand as well as the
membrane-bound precursor ligand, which should predo-
minate in the cell lysates.
AREG concentrations in cell lysates show the same
general pattern as observed for the shed ligand found in
the CM (Figure 2A). Even so, AREG concentrations in
the cell lysates are significantly greater than those in the
media. Therefore, the amount of AREG shedding appears
to be primarily dependent on its cellular concentration.
In contrast to AREG, TGF-a concentrations in the
cell lysates are relatively constant across all three cell
lines (Figure 2B). If the presence of HER2/HER3 does
not affect protease activity that is responsible for ligand
shedding, similar amounts of shed TGF-a would be pre-
dicted. Instead, our results show that there is more
accumulation of shed TGF-a in cell lines expressing ele-
vated levels of HER2 or HER3 (Figure 1D). This result
suggests that, in contrast to AREG, factors other than
just cellular levels of TGF-a influence the process of
ligand accumulation in the CM.
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HER2 or HER3 Expression do not Affect AREG and TGF-a
mRNA Levels
Our analysis of ligand concentrations in CM and cell
lysate clearly suggests that HER receptors regulate ligand
shedding at the level of cellular protein expression. These
results are consistent with several lines of evidence that
show that the expression of HER ligands increases at both
the mRNA and protein levels in many invasive breast
tumors, and that ligand mRNA levels in breast cancer cell
lines or breast cancer correlate with their respective pro-
tein levels [27]. Therefore, we used quantitative RT-PCR
analysis to determine if the presence of HER receptors on
HMEC regulated HER ligand expression at the mRNA
level. Examples of mRNA levels for two ligands, AREG
and TGF-a, are shown in Figure 3. Basal levels of AREG
mRNA and TGF-a mRNA were similar in both parental
(HER1) and HER2 cell lines. The HER3 cell line expressed
slightly higher levels of AREG mRNA but lower levels of
TGF-a mRNA than the other two cell lines. In all three
cell lines, EGF treatment up-regulated the expression of
AREG and TGF-a genes within 2 h. Similar expression












































































Figure 1 Time course of HER ligand secretion in HME cell lines expressing different levels of HER receptors after addition of 12 ng/ml
EGF to the culture medium. Conditioned medium (CM) was collected at 0, 0.5, 2, 8 and 24 h after EGF addition, and ELISA microarray analysis
was used to determine the concentrations of A) EGF, B) AREG, C) HB-EGF and D) TGF-a in CM samples from the parental HER1 cell line
(diamonds), HER2 (squares, cell line engineered to overexpress HER2 in addition to the endogenous expression levels of HER1 receptor) and
HER3 (triangles, a cell line engineered to overexpress HER3 and has endogenous expression levels of HER1). Except at t = 24 h, EGF
concentrations were over the detection limit. Therefore, EGF concentrations at early time points are omitted. Data points and crossbars represent
the mean and standard deviation of five replicates, each from a separate culture dish. The symbols denote statistically significant differences
between the parental HER1 and HER2 (*) or HER3 (#) by both analysis of variance and Fisher’s protected least significant difference analysis.
Zhang et al. BMC Cancer 2011, 11:69
http://www.biomedcentral.com/1471-2407/11/69
Page 6 of 20
cell lines during the 24 h time course. Since we did not
observe significant differences in mRNA levels for these
ligands between the three cell lines, we concluded that the
presence of HER2 or HER3 in the HMEC did not signifi-
cantly alter the pathways that regulate AREG and TGF-a
expression upon activation of HER1. These results imply
that the production rates of both AREG and TGF-a are
similar in all the three cell lines, regardless of the presence
of elevated levels of HER2 or HER3. This conclusion
further implies that the differences in HER1 ligand con-
centrations in CM and cell lysates that we observed in
these cell lines mainly result from ligand secretion and
trafficking and, potentially, subsequent degradation.
Accumulation of shed HER Ligands is Mediated by Both
MAPK/Erk and PI3K/Akt Pathways
HER receptor and ligand autocrine/paracrine signaling











































Figure 2 Time-dependent changes of HER ligand concentrations in cell lysates. HMEC lines expressing different levels of HER receptors
were treated with 12 ng/ml EGF for up to 24 h. Cell lysates were collected at t = 0, 0.5, 2, 8 and 24 h, and ELISA microarray analysis was used
to determine the concentration of A) AREG and B) TGF-a in cell lysates from the parental HER1 cell line (diamonds), HER2 (squares) and HER3
(triangles). Results are presented as ng ligand per mg cell-lysate protein. Data points and crossbars represent the mean and standard deviation
of five replicates, each from a separate culture dish. The symbols denote statistically significant differences between the parental HER1 and HER2































Figure 3 Analysis of mRNA levels of HER1 ligands. Relative mRNA levels of A) AREG and B) TGF-a were determined in HMEC parental HER1
(diamonds), HER2 (squares) and HER3 (triangles) cell lines using quantitative RT-PCR, as described in the Methods. Total RNA was extracted from
cell samples treated with 12 ng/ml EGF for 0, 0.5, 2, 8 or 24 h. mRNA expression for each gene was normalized with respect to its expression in
the parental HER1 cells at t = 0 h. Data points and crossbars represent the mean and standard deviation of three replicates, each from a
separate culture dish. The symbols denote statistically significant differences between the parental HER1 and HER2 (*) or HER3 (#) by both
analysis of variance and Fisher’s protected least significant difference analysis.
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autocrine stimulation of the HER receptor can lead to
sustained increases in Erk phosphorylation [47,48].
Furthermore, MAPK kinases also control the proteolytic
release of certain HER receptor ligands [49,50]. In this
study, we examined Erk and Akt phosphorylation levels
in HMEC at 0.5, 2, 8 and 24 h following EGF stimula-
tion. This analysis showed that both phospho-Erk and
phospho-Akt signals peaked at ~0.5 h and then gradu-
ally dropped to basal level at 8 h (Figure 4A + B). As
both MAPK/Erk and PI3K/Akt are key pathways acti-
vated by HER1 signaling, we used chemical inhibitors to
independently block each of these signal pathways, with
the goal of determining their roles in HER1-dependent
ligand shedding in the HMEC lines. We observed that
two MAPK inhibitors (25 µM PD98059 and 10 µM
U0126) and two PI3K inhibitors (20 µM LY94002 and
200 nM wortmannin) could block more than 80% of
Erk and Akt activation induced by EGF stimulation,
respectively (Figure 4C + D). In addition, each of these
inhibitors significantly reduced accumulation of the shed
ligands in the CM of all three cell lines, indicating both
pathways support HER ligand secretion (Figure 5).
HER Receptor Shedding is Detectable, but is at Low
Levels in HMEC
HER receptors undergo shedding in a similar (i.e., pro-
tease-dependent) mechanism as their ligands. In this
study, we examined the level of both HER1 and HER2
shedding over a 24 h period after initiation of EGF
treatment of each cell line. All three HMEC lines we
studied express ~2x105 HER1 per cell. As shown in
Figure 6A, detectable amounts of shed HER1 were
observable 8 h after initiation of EGF treatment. This
shedding process was not dependent upon EGF treat-
ment, since at 8 h there was no significant difference
between samples with or without EGF addition (data
not shown). After 8 h, HER1 shedding gradually acceler-
ated, with a faster rate in the HER2 and HER3 cell lines.
On the other hand, HER1 concentrations in the cell
lysates remained at a relatively constant level during the
24 h time course (Figure 6B). The maximum concentra-
tion of HER1 in the CM was 1000 pg/ml at 24 h, sug-
gesting that a total of ~1 ng HER1 was shed from
HMEC. Since HER1 concentration in cell lysate is about
50 ng per mg protein of cell lysate and there is about
0.32 mg cell lysate collected from each sample (see
Methods), the total amount of HER1 present in cell
lysate is approximately 16 ng. Thus, our results show
that the total shed HER1 that accumulates over 24 h is
approximately 6% of its steady-state cellular level (1 ng
in the CM compared to 16 ng in the cell lysate). Similar
results were obtained for HER2 shedding in the HER2
cells (Figure 6C + D). Overall, even though HER1 and
HER2 receptors are shed at detectable levels, our data
suggest that this is not a significant mechanism for the
down-regulation of these receptors in the HMECs.
Matrix Metalloproteinase Secretion is Induced upon HER
Activation
The expression and secretion of MMPs are closely asso-
ciated with cancer cell invasion and metastasis. The pro-
teolytic degradation of extracellular matrix components
by MMPs is believed to be required in these metastatic
processes [51,52]. MMPs have also been examined as
candidate prognostic markers in many types of human
cancers [53]. Growth factors have been reported to reg-
ulate secretion and activation of various MMPs at both
transcriptional level and at the cellular protein level
[54]. In this study, we examined the secretion of MMP1,
MMP2 and MMP9 in our three HMEC lines following
HER1 activation (Figure 7). Our results show that the
secretion pattern of MMP2 is not significantly different
among the three HMEC lines. Cellular MMP2 concen-
trations were also similar among the three cell lines.
MMP2 secretion is independent of HER1 activation
since EGF-treated HMECs release the same amount of
MMP2 as untreated cells (Figure 8B). Furthermore, we
observe that this constitutive MMP2 secretion is not
affected by either MAPK/Erk or PI3K/Akt pathway,
since the inhibitors of these pathways have no clear
effect on MMP2 secretion (Figure 8B).
Readily detectable levels of secreted MMP1 were
observed in all three cell lines. The secretion pattern of
MMP1 correlated with its cellular protein concentration
(Figure 7A + B), suggesting that MMP1 secretion was
regulated by its cellular expression levels. Interestingly,
we observed that secretion of MMP1 was regulated by
EGF stimulation and controlled by MAPK/Erk and
PI3K/Akt pathways in both parental and HER3 cells, but
not in HER2 cells (Figure 8A).
In contrast to MMP1, secretion of MMP9 was much
higher in the HER1 cells than the HER2 or HER3 cell
lines (Figure 7E). MMP9 secretion in the HER1 cells
was sensitive to EGF stimulation and both MAPK/Erk
and PI3K/Akt inhibitors (Figure 8C). Similar levels of
MMP9 were observed in the cell lysates of all three cell
lines. Taken together, our results suggest that increased
HER2 or HER3 expression attenuates MMP9 secretion
induced by HER1 activation.
Secretion of Various Cytokines and Angiogenic Factors is
Triggered by HER Activation
We used the ELISA microarray to analyze four pro-
inflammatory cytokines, IL-1a, IL-18, RANTES and
TNF-a, and five fibrogenic and angiogenic factors,
including bFGF, PDGF, VEGF, HGF and IGF [41]. How-
ever, because the concentrations of TNF-a, bFGF, IGF
and HGF in CM were essentially undetectable in our
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Figure 4 Erk and Akt activation in response to EGF stimulation in HMEC. Phosphorylation levels of A) Erk and B) Akt were examined in
HMEC parental HER1 cell (diamonds), HER2 (squares) and HER3 (triangles) using a commercial 96-well-plate ELISA. Lysate sample were collected
from cells treated with 12 ng/ml EGF for 0, 0.5, 2, 8 and 24 h. Results are presented as ng pErk or pAkt per mg lysate protein. Phosphorylation
level of C) Erk and D) Akt were also examined when cells were pretreated with MAPK inhibitors (25 µM PD98059 and 10 µM U0126) and PI3K
inhibitors (20 µM LY94002 and 200 nM wortmannin). Data points (or columns) and cross bars represent the average and standard deviation,
respectively, of two biological replicates, each from a separate culture dish. In panels A and B, the symbols denote statistically significant
differences between the parental HER1 and HER2 (*) or HER3 (#) by t-test. In panels C and D, results were normalized based on the
phosphorylation level of the control sample (0.1% DMSO alone) from the parental HER1 cells after 0.5 h EGF stimulation. In the presence of
wortmannin, Akt phosphorylation levels of parental HER1 cell line at t = 2 hr and HER3 cell line at t = 0.5 hr were below assay detection limit.
The asterisks in panel C and D denote statistically significant differences between inhibitor-treated sample and its control (0.1% DMSO in
absence of any inhibitor) in each individual cell line at every time point.
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Figure 5 Effect of MAPK/Erk and PI3K/Akt pathway inhibitors on HER1 ligand secretion. HMEC lines expressing different levels of HER
receptors were preincubated with a single inhibitor (20 μg/ml LY 294002, 200 nM wortmannin, 25 µM PD 98059 or 10 µM U0126) for 1 h,
followed by treatment with 12 ng/ml EGF for 8 h. DMSO concentration was 0.1% in all experiments except those marked as “ctrl”. Conditioned
medium (CM) was collected and the concentrations of A) AREG, B) HB-EGF and C) TGF-a were determined by ELISA microarray analysis. Ligand
concentrations were normalized with respect to the concentration in the HER1 cells treated only with 12 ng/ml EGF for 8 h. Columns and
crossbars represent the mean and standard deviation, respectively, from five replicates, each of which was from a separate culture dish. The
standard deviation is shown for every analysis, but in some cases the crossbar may be too small to be visible. The asterisks denote statistically
significant differences between inhibitor-treated cells and ctrl cells for the individual cell lines, as determined by both analysis of variance and by
Fisher’s protected least significant difference.
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assay system, results from these four proteins are not
reported here.
For the three detectable pro-inflammatory cytokines,
HER expression levels had qualitatively similar effects
on protein concentrations in CM and in cell lysates
(Figure 9). For example, RANTES concentration was sig-
nificantly higher in both CM and cell lysates of HER2 cells
than in the other two cell lines. Similar results were
observed for RANTES mRNA levels (Figure 10B). Similar
to the HER1 ligands, these results suggest that secretion of
IL-1a, IL-18 and RANTES are largely dependent upon
their cellular protein concentrations in the HMECs.
Our results show that, while IL-18 concentration in
CM decreased during the first 0.5 hour of the experiment,
both IL-1a and RANTES concentrations continuously
increase for the duration of the 24 h experimental period
(Figure 9). Although similar temporal patterns of these
proteins were observed in all three cell lines, absolute con-
centrations of these cytokines were consistently greater in
the HER2 and HER3 cell lines.
In the cell lysates, IL-1a concentration gradually
increased and peaked at 4 to 8 h after initiation of
EGF stimulation, particularly in HER2 and HER3 cells
(Figure 9B). After 8 h, IL-1a concentrations declined,
possibly due to a sustained level of IL-1a secretion
and a decreased rate of protein synthesis at the later
time. This supposition is supported by the RT-PCR



















































































Figure 6 Time courses of HER receptor concentration change. HME cell lines expressing different levels of HER receptors were treated with
12 ng/ml EGF for up to 24 h. Both CM and its corresponding cell lysate were collected at t = 0, 0.5, 2, 8 and 24 h. Concentrations of HER1
(EGFR) and HER2 in CM (A and C) and cell lysate (B and D) were detected from samples of parental HER1 (diamonds), HER2 (squares) and HER3
(triangles) cell lines. Error bars represent one standard deviation from the mean of five biological replicates. The asterisks denote statistically
significant differences between HER1 and HER2 (*) or HER3 (#) by both analysis of variance and Fisher’s protected least significant difference
analysis.
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Figure 7 Time courses of MMP concentration change. HME cell lines expressing different levels of HER receptors were treated with 12 ng/ml
EGF for up to 24 h. Both CM and its corresponding cell lysate were collected at t = 0, 0.5, 2, 8 and 24 h. Concentrations of MMP1, MMP2 and
MMP9 in CM (A, C and E) and cell lysate (B, D and F) were detected from samples of parental HER1 cell line (diamonds), HER2 (squares) and
HER3 (triangles). Error bars represent one standard deviation from the mean of five biological replicates. The asterisks denote statistically
significant differences between HER1 and HER2 (*) or HER3 (#) by both analysis of variance and Fisher’s protected least significant difference
analysis.
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Figure 8 Effect of MAPK/Erk and PI3K/Akt pathway inhibitors on MMP secretion. HME cell lines expressing different levels of HER receptors
were preincubated with one of the following inhibitors (20 μg/ml LY 294002, 200 nM wortmannin, 25 µM PD 98059 or 10 µM U0126) for 1 h,
followed by the treatment with 12 ng/ml EGF for 8 h. DMSO concentration was 0.1% in all the different cell culture media except those marked
as “ctrl” runs, which lacked any DMSO. CM was collected and concentration of accumulated A) MMP1, B) MMP2 and C) MMP9 in CM were
detected from samples of parental HER1 cell line, HER2 and HER3 cell lines. Each ligand concentrations was normalized with respect to its
concentration in the parental HER1 cells that had been treated with 12 ng/ml EGF for 8 h. Error bars represent one standard deviation from the
mean of five biological replicates. The asterisks denote statistically significant differences between treated samples and ctrl runs with EGF in each
cell line by both analysis of variance and Fisher’s protected least significant difference analysis.
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Figure 9 Time courses of cytokine concentration change. HME cell lines that express different levels of HER receptors were treated with
12 ng/ml EGF for up to 24 h. Both CM and its corresponding cell lysate were collected. Concentrations of IL-1a, IL-18 and RANTES in CM (A, C
and E) and cell lysate (B, D and F) were detected from samples of parental HER1 cell line (diamonds), HER2 (squares) and HER3 (triangles). Error
bars represent one standard deviation from the mean of five biological replicates. The symbols denote statistically significant differences
between HER1 and HER2 (*) or HER3 (#) by both analysis of variance and Fisher’s protected least significant difference analysis.
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suppressed in the HER2 and HER3 cells 24 h after the
start of EGF treatment (Figure 10A). Data from our
RT-PCR experiments also showed that increases in
RANTES mRNA in HER3 were detectable starting at
2 h after EGF treatment (Figure 10B), corresponding
to the gradually increasing RANTES concentration in both
CM and cell lysates of this cell line (Figure 9E + F).
It should be noted that the CM levels of IL-1a, IL-18
and RANTES after 8 h of EGF treatment were signifi-
cantly lower than their peak levels at other sampling
time points (Figure 9), making it difficult to determine
the effect of MAPK and PI3K inhibitors on their secre-
tion at this time point. The only exception was the
prominent RANTES concentration in HER2 cell lines
(Figure 9E). In the experiment using MAPK and PI3K
inhibitors, we did not observe a significant change in
the RANTES concentration due to these inhibitors
(data not shown), suggesting that secretion of RANTES
is independent of both MAPK/Erk and PI3K/Akt
pathways.
Very similar secretion patterns of VEGF and PDGF
were observed, in that both proteins continued to accu-
mulate throughout the 24 h experiment (Figure 11A
and 11C), with a slightly higher rate in HER2 and HER3
cell lines during the first 8 h. Our results show that
secretion of VEGF is a fast and prominent response to
EGF stimulation and that this process is mediated
through both MAPK/Erk and PI3K/Akt pathways
(Figure 12A). A similar concentration pattern of VEGF
was observed in the cell lysates, as VEGF concentration
increased rapidly in the lysates upon EGF stimulation
and peaked at 8 h, with a significantly higher level in
HER2 cells. On the other hand, secretion of PDGF does
not seem to be a direct response to EGF stimulation,
since PDGF concentration in CM at 8 h of EGF stimula-
tion was not significantly different from cells not stimu-
lated by EGF treatment (Figure 12B). These results
further indicate that PDGF secretion, at least in this cell
context, is not a MAPK/Erk and PI3K/Akt dependent
process.
Discussion
In this study, we examined protein secretion patterns in
HMEC upon HER1 receptor activation. This group of
proteins not only includes HER receptors and ligands,
but a variety of MMPs, cytokines and growth factors
that regulate cellular behavior in both normal and
pathological conditions. All of these proteins have been
associated with the development of a variety of epithelial
cancers, including breast cancer; and many of them have
been investigated as potential cancer biomarkers. Our
goal in this study was to better understand the underly-
ing mechanism that links HER receptor activation and
biomarker secretion. In particular, by examining three
HMEC lines that express different levels of HER recep-
tors, we attempted to determine the influence of these
receptors on the biomarker secretion and their regula-
tory mechanisms.
Our results suggest that increased HER2 and HER3
expression potentiates ligand induced autocrine and
paracrine signaling resulting from EGF activation of
HER1. Elevated levels of HER2 or HER3 expression
increased HER1 ligand secretion, suggesting an increase































Figure 10 RT-PCR analysis of IL-1a and RANTES. Relative mRNA levels of A) IL-1a and B) RANTES gene expression were examined in HMEC
parental HER1 cell (diamonds), HER2 (squares) and HER3 (triangles) using quantitative RT-PCR. Total RNA was extracted from cell samples treated
with 12 ng/ml EGF for 0, 0.5, 2, 8 or 24 h. Each mRNA expression level was normalized with respect to its expression in parental cells at t = 0 h.
Error bars represent one standard deviation from the mean of three biological replicates. The symbols denote statistically significant differences
between HER1 and HER2 (*) or HER3 (#) by both analysis of variance and Fisher’s protected least significant difference analysis.
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with HER1 activation (Figure 1). The differences in
EGF consumption rate among the three HMEC lines
clearly imply that the presence of HER2 or HER3
accelerates HER1 ligand consumption. In contrast to
EGF (which is not synthesized by the HMECs), the
changes in concentration of AREG, HB-EGF and TGF-
a reflect the net balance of two essential processes in
this autocrine system: ligand cleavage from the synthe-
sized precursors on cell membrane and ligand binding/
consumption through receptor capture and internaliza-
tion. Because there is a large molar-excess of EGF in
the culture medium compared to the secreted HER1
ligands in the early time points of our experiments, it
seems likely that the high concentrations of EGF
effectively outcompetes the relatively low concentra-
tions of secreted ligands for binding sites on HER1.
Thus, the steady accumulation of the secreted HER1
ligands in the CM during those early time points is
likely to primarily reflect the rate of ligand shedding.
At later time points, when the EGF levels are mostly
depleted, the loss of the secreted ligands from the CM
likely reflects consumption associated with HER1 bind-
ing. All three secreted ligands can contribute to auto-
crine signaling through HER receptors [32], and all
four HER1 ligands assayed here possess similar EC50
values for activating HER1 receptor. Even so, ligand
binding has been reported to be strengthened when
















































































Figure 11 Time courses of VEGF and PDGF concentration change. HME cell lines that expressed different levels of HER receptors were
treated with 12 ng/ml EGF for up to 24 h. Both CM and its corresponding cell lysate were collected at t = 0, 0.5, 2, 8 and 24 h. Concentrations
of VEGF and PDGF in CM (A and C) and cell lysate (B and D) were measured in samples of parental HER1 (diamonds), HER2 (squares) and HER3
(triangles) cell lines. Error bars represent one standard deviation from the mean of five biological replicates. The symbols denote statistically
significant differences between HER1 and HER2 (*) or HER3 (#) by both analysis of variance and Fisher’s protected least significant difference
analysis.
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Since, the first step in ligand consumption is binding
to the receptor, followed by endocytosis of the recep-
tor-ligand complex and protein degradation, it seems
likely that enhancement of HER1 ligand-binding affi-
nities due to increased HER1 dimerization with HER2
or HER3 accounts for the increased EGF consumption
observed in the HER2 and HER3 cell lines in the early
time points, and increased consumption of other HER
ligands at the later time points. It should be noted
that, once endocytosed, some HER ligands are not
degraded, but they are recycled back to the cell mem-
brane along with HER receptors and are then released
from the cell. Compared to HER1, recycling of HER2/
HER3 is more prominent [56]. This recycling property
potentially may contribute to the increased accumula-
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Figure 12 Effects of MAPK/Erk and PI3K/Akt pathway inhibitors on cytokine secretion in HME cell lines that express different levels of
HER receptors. All cell lines were preincubated with one inhibitor (20 μg/ml LY 294002, 200 nM wortmannin, 25 µM PD 98059 or 10 µM
U0126) for 1 h, followed by treatment with 12 ng/ml EGF for 8 h. DMSO concentration in the culture media was 0.1% in all the experiments
except those marked as “ctrl” runs, which lacked any DMSO. CM was collected from the parental HER1, HER2 and HER3 cell lines and
concentrations of accumulated A) VEGF and B) PDGF were determined by ELISA microarray analysis. The concentration of each growth factor
was normalized with respect to its concentration in the HER1 cells that were treated with 12 ng/ml EGF for 8 h. Error bars represent one
standard deviation from the mean of five biological replicates. The asterisks denote statistically significant differences between treated samples
and ctrl runs with EGF in each cell line by both analysis of variance and Fisher’s protected least significant difference analysis.
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All HER ligands measured in this study can initiate
phosphorylation of HER receptors and lead to down-
stream signal transduction, including the activation of
MEK/Erk and PI3K/Akt pathways [1]. Activation of Erk
and Akt can provide critical cell mitogenic and survival
signals required for tumor progression. Components of
these two pathways are frequently abnormal in a variety
of cancer tumors and may represent biologically relevant
targets for anti-cancer therapy [57-59]. In addition, MEK
pathway activation can induce transcriptional activation
of HER ligands like TGF-a [59]. Our observation that
inhibitors of MAPK/Erk largely blocked HER ligand
secretion emphasizes the importance of this pathway in
HER autocrine signaling. We also identified a regulatory
role of PI3K/Akt in this process (Figure 5). We do not
know of any prior reports that identify this pathway in
HER1 autocrine signaling. Our study finds that both of
these signaling pathways can regulate HER activation by
stimulating ligand synthesis and, subsequently, shedding.
In addition to HER ligands, we detected the shedding
of HER1 and HER2 in HMEC. Changes in the circulat-
ing levels of HER receptors have been reported in a
variety of different cancers. Elevated circulating HER2
levels have been identified in a group of patients with
HER2-positive breast cancer with significantly worse
outcome [60-62]. In contrast, patients diagnosed with
ovarian, head and neck, non-small cell lung cancer dis-
play lower serum HER1 concentrations, and changes of
serum HER1 concentration have been correlated with
the efficiency of cancer treatment [11]. In this study, we
did not observe prominent HER1 or HER2 shedding in
HMEC, even in cells that overexpress HER2 (Figure 6).
Our results are consistent with a recent report that
investigated HER1 shedding in malignant cells [63].
Their results showed that among a few malignant cell
lines, HER1 shedding only occurred in cell lines that
express more than 7x105 HER1 per cell and were
treated for 8 h or more with phorbol 12-myristate
13-acetate.
MMPs are widely expressed by many types of cells.
High levels of MMPs are associated with tumor invasion
and metastasis [54]. Previously, we reported that TNF-a
stimulation could induce production of MMP9 in our
parental HMEC, the HER1 cell line, and that this pro-
cess was dependent on autocrine signaling that activated
HER1 [64]. In this study, we examined the secreted
levels of MMP1, 2 and 9 after EGF treatment. The
results show that MMP2 levels are similar among all the
three HMEC lines and that EGF treatment does not
increase MMP2 levels. Thus, it appears that MMP2
secretion is not regulated by HER receptor activity. In
contrast, MMP1 expression and secretion were induced
in response to HER signaling. Notably, increased levels
of the HER2 receptor enhance basal MMP1 secretion
(Figure 8A). In parental cells and HER2 cells, induction
of MMP1 expression can be triggered only through
ligand-induced HER1 activation. Interestingly, induction
of MMP9 secretion by EGF signaling was only observed
in parental cells, implying the presence of HER2 or
HER3 may repress MMP9 secretion in response to
HER1 activation by an undefined mechanism.
Our conclusion that MMP secretion is mediated by
the Erk pathway is in agreement with previous reports
[65-68]. We also observe that the Akt pathway has a
role in MMP secretion (Figure 8). As inhibition of
MMP secretion through blockade of either pathway is
only effective when secretion is stimulated by HER
receptor activation, these results indicate that Erk and
Akt pathways mediate MMP secretion through HER sig-
naling in HMEC. Overall, these results suggest that
secretion of these three MMP forms are regulated by
distinct molecular processes and, thus, that their use as
biomarkers may provide differential insight into cell-sig-
naling processes occurring in breast cancer cells.
Cytokines play an important role in the pathogenesis
of cancers. Secretion of most cytokines undergo traffick-
ing through the Golgi [69], and are not dependent on
proteolytic shedding. In this study, we found that activa-
tion of HER signaling could trigger the release of cyto-
kines in the HMEC systems, apparently through
increased synthesis of the cytokines (Figure 10).
Continuous accumulation of both PDGF and VEGF
was observed in all the HMEC lines. Even so, our results
suggest that the regulatory mechanisms that control the
secretion of these two proteins are distinct. In HMEC,
secretion of PDGF seems to be a constitutive process
that is independent of Erk and PI3K/Akt pathways. In
contrast, synthesis and secretion of VEGF is a direct and
spontaneous response to HER signaling through EGF
stimulation, and both MAPK/Erk and PI3K/Akt path-
ways appear to have a role in VEGF secretion. Our
results are consistent with previous studies that demon-
strate that HER1 regulates VEGF expression in a variety
of different cancer cell lines [70].
Conclusion
In summary, we examined the interaction between HER
receptor levels and protein secretion in HMEC, with the
dual goals of gaining insight into the molecular pro-
cesses that regulate the secretion of proteins that influ-
ence cancer development and progression, and therefore
may serve as biomarkers that can be used to assess
molecular events in tumor tissue. By studying the secre-
tion patterns of a panel of proteins that are associated
with a variety of human cancers, we gained novel insight
into how HER activation results in a concerted change
in multiple classes of secreted proteins that not only
alter the cellular microenvironment through matrix
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reconstruction, angiogenesis, and paracrine interactions
with stromal and immune cells, but also provide auto-
crine feedback to the tumor epithelial cells that results
in further enhanced growth and migration. Therefore,
this study suggests that changes in protein secretion
may be an important factor by which HER activation
stimulates mammary tumor formation.
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